Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy.
C3a
C5a
Fabry disease
complement
enzyme replacement therapy
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2024
2024
Historique:
received:
04
10
2023
accepted:
03
01
2024
medline:
2
2
2024
pubmed:
2
2
2024
entrez:
2
2
2024
Statut:
epublish
Résumé
Defective α-galactosidase A (AGAL/GLA) due to missense or nonsense mutations in the
Identifiants
pubmed: 38304433
doi: 10.3389/fimmu.2024.1307558
pmc: PMC10830671
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1307558Informations de copyright
Copyright © 2024 Laffer, Lenders, Ehlers-Jeske, Heidenreich, Brand and Köhl.
Déclaration de conflit d'intérêts
KH was employed by the company Eleva GmbH. JK received advisory fees from Eleva GmbH. ML received speaker honoraria, travel funding and research grants from Amicus Therapeutics, Sanofi Genzyme, Chiesi, and Shire/Takeda. EB received research grants and speaker honoraria from Sanofi Genzymem Shire/Takeda, Chiesi, Eleva GmbH and Amicus Therapeutics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest. The authors declare that this study received funding from Eleva GmbH. The funder was involved in the study design, review and editing of the manuscript.